Results 1 to 10 of about 134,020 (288)

Effects of Cordycepin in Cordyceps militaris during Its Infection to Silkworm Larvae

Microorganisms, 2021
Cordyceps militaris produces cordycepin, a secondary metabolite that exhibits numerous bioactive properties. However, cordycepin pharmacology in vivo is not yet understood. In this study, the roles of cordycepin in C.
Tatsuya Kato, Konomi Nishimura, Ahmad Suparmin, Kazuho Ikeo, Enoch Y. Park   +4 more
doaj   +1 more source

Quercetin as a potential treatment for COVID-19-induced acute kidney injury: Based on network pharmacology and molecular docking study.

PLoS ONE, 2021
Kidneys are one of the targets for SARS-CoV-2, it is reported that up to 36% of patients with SARS-CoV-2 infection would develop into acute kidney injury (AKI).
Yue-Yu Gu, Min Zhang, Huan Cen, Yi-Fan Wu, Zhaoyu Lu, Fuhua Lu, Xu-Sheng Liu, Hui-Yao Lan   +7 more
doaj   +1 more source

Determination of PAR4 numbers on the surface of human platelets: no effect of the single nucleotide polymorphism rs773902

Platelets, 2021
The thrombin receptor, protease-activated receptor 4 (PAR4), is important for platelet activation and is the target of emerging anti-thrombotic drugs. A frequently occurring single nucleotide polymorphism (SNP; rs773902) causes a function-altering PAR4 ...
Simeng Li, Volga Tarlac, Roberto B. I. Christanto, Shauna L. French, Justin R. Hamilton   +4 more
doaj   +1 more source

Management of Antiretroviral Therapy with Boosted Protease Inhibitors—Darunavir/Ritonavir or Darunavir/Cobicistat

Biomedicines, 2021
A major challenge in the management of antiretroviral therapy (ART) is to improve the patient’s adherence, reducing the burden caused by the high number of drugs that compose the treatment regimens for human immunodeficiency virus positive (HIV ...
Ruxandra-Cristina Marin, Tapan Behl, Nicoleta Negrut, Simona Bungau   +3 more
doaj   +1 more source

Pharmacological Inhibition of MALT1 Protease Leads to a Progressive IPEX-Like Pathology

Frontiers in Immunology, 2020
Genetic disruption or short-term pharmacological inhibition of MALT1 protease is effective in several preclinical models of autoimmunity and B cell malignancies. Despite these protective effects, the severe reduction in regulatory T cells (Tregs) and the
Kea Martin, Ursula Junker, Elaine Tritto, Esther Sutter, Tina Rubic-Schneider, Hannah Morgan, Satoru Niwa, Jianping Li, Achim Schlapbach, Dana Walker, Marc Bigaud, Christian Beerli, Amanda Littlewood-Evans, Bettina Rudolph, Marc Laisney, David Ledieu, Karen Beltz, Jean Quancard, Frédéric Bornancin, Natasa Zamurovic Ribrioux, Thomas Calzascia   +20 more
doaj   +1 more source

Treatment of Porphyromonas gulae infection and downstream pathology in the aged dog by lysine-gingipain inhibitor COR388. [PDF]

, 2020
COR388, a small-molecule lysine-gingipain inhibitor, is currently being investigated in a Phase 2/3 clinical trial for Alzheimer's disease (AD) with exploratory endpoints in periodontal disease.
Arastu-Kapur, Shirin, Araujo, Joseph, De Lannoy, Ines AM, Dominy, Stephen S, Ermini, Florian, Haditsch, Ursula, Holsinger, Leslie J, Lynch, Casey, Nguyen, Mai, Raha, Debasish, Ryder, Mark I   +10 more
core   +1 more source

Myricetin, the main flavonoid in Syzygium cumini leaf, is a novel inhibitor of platelet thiol isomerases PDI and ERp5 [PDF]

, 2020
Background: Flavonoids have been characterized as a prominent class of compounds to treat thrombotic diseases through the inhibition of thiol isomerases. Syzygium cumini is a flavonoid-rich medicinal plant that contains myricetin and gallic acid.
Ayyanar, Banno, Bekendam, Bi, Chagas, Chagas, Chang, Chen, Chung, Dang, De Bona, Dutta-Roy, Essex, Essex, Essex, Ghoshal, Giamogante, Giamogante, Holbrook, Inoue, Jarvis, Jasuja, Jayakumar, Jordan, Kang, Kehrel, Kim, Lahav, Lakowicz, Lescano, Lin, Lu, Mangin, Masuda, Navarro-Nuñez, Park, Raffaelli, Raturi, Sharma, Sousa, Stopa, Taylor, Trnkova, Wang, Ware, Wendelboe   +45 more
core   +1 more source

Low lopinavir plasma or hair concentrations explain second-line protease inhibitor failures in a resource-limited setting. [PDF]

, 2011
In resource-limited settings, many patients, with no prior protease inhibitor (PI) treatment on a second-line, high genetic barrier, ritonavir-boosted PI-containing regimen have virologic ...
Arribas, Bangsberg, Barreiro, Berg, Carolina Malavazzi, Cassani, Delaugerre, El-Khatib, Eric Decloedt, Frost, Gandhi, Gardner, Gary Maartens, Gathe, Gert Uves van Zyl, Helen McIlleron, Huang, Jean B Nachega, Kosuge, Lize van der Merwe, Michele Zeier, Mo, Monica Gandhi, Peter Smith, Pujades-Rodriguez, Quiros-Roldan, Riddler, Thijs E van Mens, van Zyl, van Zyl, Yong Huang   +30 more
core   +6 more sources

Drug-Drug Interactions Among Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) Medications [PDF]

, 2015
One-fourth of individuals diagnosed with the human immunodeficiency virus concomitantly have the hepatitis C virus infection. Since the discovery of highly active antiretroviral therapy, liver complications have become the leading cause of morbidity and ...
Gandhi, Mona A., Kaur, Kirpal, Slish, Judianne   +2 more
core   +2 more sources

Personalizing HIV therapy, mission impossible? [PDF]

, 2012
Sustained HIV suppression depends on a number of factors including therapy adherence, management of side effects, viral resistance and individual characteristics of patients and therapeutic settings.
Hentig, Nils von
core   +1 more source